{"schema_version":"1.0","type":"article","title":"禮來領頭，大藥廠半年豪砸 1,300 億美元搶時間！","url":"https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1.md","lang":"zh-Hant","date":"2026-08-10","publish_at":"2026-08-10T08:00:00+08:00","updated_at":"2026-08-10","category":"商業分析系列","topic":"商業分析系列","tags":["生技併購","藥廠併購","專利懸崖","Eli Lilly","Merck","AbbVie","Gilead","GSK","IQVIA","Biotech"],"summary":"2026 年上半年生技製藥併購總額約 1,300 億美元，買家偏向臨床後期與接近上市的資產。這一輪不是全面牛市，而是大藥廠在專利懸崖前，用交易結構與現金購買可計算的開發時間。","key_points":[],"facts":[],"sections":["01｜52 筆與 42 筆，來自兩套統計口徑","02｜專利時鐘倒數，藥廠搶臨床時間","03｜禮來掃貨，整合與淘汰才是驗收","04｜吉利德與 GSK，押的是接近商業化的腫瘤資產","05｜最大一筆，也不能只看公告金額","06｜併購升溫，只照亮一小群 Biotech","07｜台灣讀者該看什麼？","結語｜半年千億，買的是時間","參考資料","免責聲明"],"references":[{"title":"查證截止：2026-07-19","source":"","date":"","url":""},{"title":"[BioSpace, H1 2026 M&A count and methodology]","source":"","date":"","url":"https://www.biospace.com/business/biopharma-strikes-50-m-as-deals-in-h1-led-by-lillys-25b-spend"},{"title":"[IQVIA, Biopharma M&A: Mid-year 2026 update]","source":"","date":"","url":"https://www.iqvia.com/locations/emea/blogs/2026/07/biopharma-ma-mid-year-2026-update"},{"title":"[PwC, US Deals 2026 midyear outlook]","source":"","date":"","url":"https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html"},{"title":"[Merck／Terns transaction agreement]","source":"","date":"","url":"https://www.merck.com/news/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml/"},{"title":"[Merck completion of Terns acquisition]","source":"","date":"","url":"https://www.merck.com/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc/"},{"title":"[AbbVie／Apogee transaction announcement]","source":"","date":"","url":"https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-apogee-therapeutics-deepening-immunology"},{"title":"[Gilead completion of Arcellx acquisition]","source":"","date":"","url":"https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel"},{"title":"[Gilead completion of Tubulis acquisition]","source":"","date":"","url":"https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Completes-Acquisition-of-Tubulis-Further-Strengthening-Oncology-Portfolio/default.aspx"},{"title":"[GSK／Nuvalent transaction agreement]","source":"","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/"},{"title":"[GSK completion of Nuvalent acquisition]","source":"","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/"},{"title":"[Sun Pharma／Organon definitive agreement]","source":"","date":"","url":"https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/"}],"images":[{"alt":"禮來領頭，大藥廠半年豪砸 1,300 億美元，真正買的是時間","url":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1/figure-01.png"},{"alt":"BioSpace 與 IQVIA 對 2026 年上半年生技製藥併購的不同統計口徑","url":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1/figure-03.png"},{"alt":"專利懸崖如何推動大藥廠收購臨床階段資產以換取開發時間","url":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1/figure-02.png"},{"alt":"公告金額必須拆解為前期現金、股權價值、企業價值、或有價值權、里程碑與交割條件","url":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-10）。禮來領頭，大藥廠半年豪砸 1,300 億美元搶時間！。https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-10-biopharma-ma-buying-time-2026h1-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}